Growth Metrics

NovoCure (NVCR) Income towards Parent Company (2016 - 2025)

Historic Income towards Parent Company for NovoCure (NVCR) over the last 12 years, with Q3 2025 value amounting to -$37.3 million.

  • NovoCure's Income towards Parent Company fell 2191.69% to -$37.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$177.6 million, marking a year-over-year decrease of 1860.41%. This contributed to the annual value of -$168.6 million for FY2024, which is 1855.46% up from last year.
  • Latest data reveals that NovoCure reported Income towards Parent Company of -$37.3 million as of Q3 2025, which was down 2191.69% from -$40.1 million recorded in Q2 2025.
  • NovoCure's 5-year Income towards Parent Company high stood at -$4.1 million for Q1 2021, and its period low was -$65.9 million during Q4 2024.
  • In the last 5 years, NovoCure's Income towards Parent Company had a median value of -$34.3 million in 2025 and averaged -$33.6 million.
  • Its Income towards Parent Company has fluctuated over the past 5 years, first tumbled by 104183.34% in 2023, then surged by 4187.36% in 2024.
  • Quarter analysis of 5 years shows NovoCure's Income towards Parent Company stood at -$26.5 million in 2021, then tumbled by 40.99% to -$37.3 million in 2022, then decreased by 26.21% to -$47.1 million in 2023, then plummeted by 40.02% to -$65.9 million in 2024, then soared by 43.46% to -$37.3 million in 2025.
  • Its Income towards Parent Company stands at -$37.3 million for Q3 2025, versus -$40.1 million for Q2 2025 and -$34.3 million for Q1 2025.